

Remarks

This Preliminary Amendment is submitted to insert the statement of the relation of this application to prior related applications, and is submitted to insert the Abstract, which was originally included on the first page of the corresponding International application, as the last page of the specification. No new matter has been added by these amendments to the specification.

Support for new claims 31-42 can be found in Example 15, from page 45, line 4, to page 52, line 9. At page 45, lines 11-13, the application states in part that “[t]he methods ... for improving neurite outgrowth, include the use of any bastadin or any member of the bastadin family, or their analogs.” The application discloses that “[a] compound from the bastadin family refers to subunits of the bastadins, such as halogenated tryosines, including bromotryosines” and “hemibastadins, which represent bromotryosine dimers.” It also states that “hemibastadins include hemibastadins 1, 2, and 3 as well as hemibastadinols 1, 2, and 3.” Structures of exemplary bastadin subunits also are provided in Example 15 along with exemplary structures of complete bastadins, which are clearly recognizable as bromotyrosine tetramers. Complete bastadins and their subunits (that is the hemibastadins, hemibastadinols and bromotryosines) also are discussed from page 6, lines 1, to page 7, line 21.

Support for new claims 43-52 can be found, for example, at page 5, lines 1-17, where the application discusses the use of additional neurotrophic compounds, heat and templates in the disclosed method.

Support for new claims 53-69 can be found, for example, from page 3, line 28, to page 4, line 13; in Example 15, from page 45, line 4, to page 52, line 9; from page 6, lines 1, to page 7, line 21; and in Example 21, from page 55, line 17, to page 57, line 32.

Support for new claim 70 can be found, for example, in original claim 17.

No new matter is introduced in new claims 31-70.

Conclusion

If any matters of form remain to be corrected prior to examination and allowance of this application, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Aden A. Rehms, Ph.D.
Registration No. 55,935

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446